Logo image of MDXH

MDXHEALTH (MDXH) Stock Fundamental Analysis

NASDAQ:MDXH - Nasdaq - BE0974461940 - Common Stock - Currency: USD

1.86  0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MDXH. MDXH was compared to 572 industry peers in the Biotechnology industry. MDXH has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, MDXH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MDXH had negative earnings in the past year.
MDXH had a negative operating cash flow in the past year.
MDXH had negative earnings in each of the past 5 years.
MDXH had a negative operating cash flow in each of the past 5 years.
MDXH Yearly Net Income VS EBIT VS OCF VS FCFMDXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

MDXH has a Return On Assets (-45.37%) which is in line with its industry peers.
Industry RankSector Rank
ROA -45.37%
ROE N/A
ROIC N/A
ROA(3y)-36.32%
ROA(5y)-60.99%
ROE(3y)-377.78%
ROE(5y)-369.25%
ROIC(3y)N/A
ROIC(5y)N/A
MDXH Yearly ROA, ROE, ROICMDXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

1.3 Margins

Looking at the Gross Margin, with a value of 62.69%, MDXH is in the better half of the industry, outperforming 79.93% of the companies in the same industry.
MDXH's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for MDXH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.29%
GM growth 5Y1.56%
MDXH Yearly Profit, Operating, Gross MarginsMDXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

1

2. Health

2.1 Basic Checks

MDXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MDXH has more shares outstanding
Compared to 5 years ago, MDXH has more shares outstanding
The debt/assets ratio for MDXH has been reduced compared to a year ago.
MDXH Yearly Shares OutstandingMDXH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
MDXH Yearly Total Debt VS Total AssetsMDXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -3.40, we must say that MDXH is in the distress zone and has some risk of bankruptcy.
MDXH has a Altman-Z score (-3.40) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.4
ROIC/WACCN/A
WACC8.74%
MDXH Yearly LT Debt VS Equity VS FCFMDXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.91 indicates that MDXH may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.91, MDXH is doing worse than 89.52% of the companies in the same industry.
A Quick Ratio of 0.83 indicates that MDXH may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.83, MDXH is doing worse than 90.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.91
Quick Ratio 0.83
MDXH Yearly Current Assets VS Current LiabilitesMDXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.91% over the past year.
Looking at the last year, MDXH shows a very strong growth in Revenue. The Revenue has grown by 89.45%.
The Revenue has been growing by 19.84% on average over the past years. This is quite good.
EPS 1Y (TTM)33.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)89.45%
Revenue growth 3Y56.08%
Revenue growth 5Y19.84%
Sales Q2Q%20.5%

3.2 Future

The Earnings Per Share is expected to grow by 19.68% on average over the next years. This is quite good.
The Revenue is expected to grow by 19.83% on average over the next years. This is quite good.
EPS Next Y22.81%
EPS Next 2Y28.55%
EPS Next 3Y21.85%
EPS Next 5Y19.68%
Revenue Next Year27.93%
Revenue Next 2Y23.85%
Revenue Next 3Y20.28%
Revenue Next 5Y19.83%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
MDXH Yearly Revenue VS EstimatesMDXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M
MDXH Yearly EPS VS EstimatesMDXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MDXH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDXH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDXH Price Earnings VS Forward Price EarningsMDXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDXH Per share dataMDXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as MDXH's earnings are expected to grow with 21.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.55%
EPS Next 3Y21.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDXH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MDXHEALTH

NASDAQ:MDXH (2/21/2025, 8:00:01 PM)

1.86

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners48.22%
Inst Owner Change0%
Ins Owners7.29%
Ins Owner ChangeN/A
Market Cap50.76M
Analysts86.67
Price Target6.16 (231.18%)
Short Float %0.07%
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-28.34%
Min EPS beat(2)-55.38%
Max EPS beat(2)-1.31%
EPS beat(4)0
Avg EPS beat(4)-102.13%
Min EPS beat(4)-247.59%
Max EPS beat(4)-1.31%
EPS beat(8)1
Avg EPS beat(8)-58.51%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.57%
Min Revenue beat(2)4.35%
Max Revenue beat(2)6.78%
Revenue beat(4)4
Avg Revenue beat(4)5.35%
Min Revenue beat(4)4.35%
Max Revenue beat(4)6.78%
Revenue beat(8)8
Avg Revenue beat(8)17.85%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-28.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.55%
EPS NY rev (3m)-0.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.42
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.52
EYN/A
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-0.92
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS4.39
BVpS-0.32
TBVpS-3.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.37%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.69%
FCFM N/A
ROA(3y)-36.32%
ROA(5y)-60.99%
ROE(3y)-377.78%
ROE(5y)-369.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.29%
GM growth 5Y1.56%
F-Score5
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 51.01%
Cap/Sales 3.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.91
Quick Ratio 0.83
Altman-Z -3.4
F-Score5
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)62.5%
Cap/Depr(5y)41.15%
Cap/Sales(3y)7.48%
Cap/Sales(5y)5.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y22.81%
EPS Next 2Y28.55%
EPS Next 3Y21.85%
EPS Next 5Y19.68%
Revenue 1Y (TTM)89.45%
Revenue growth 3Y56.08%
Revenue growth 5Y19.84%
Sales Q2Q%20.5%
Revenue Next Year27.93%
Revenue Next 2Y23.85%
Revenue Next 3Y20.28%
Revenue Next 5Y19.83%
EBIT growth 1Y33.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.81%
EBIT Next 3Y33.56%
EBIT Next 5Y33.05%
FCF growth 1Y10.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.58%
OCF growth 3YN/A
OCF growth 5YN/A